|
|
Volumn 97, Issue 7, 2007, Pages 844-850
|
|
First-into-man phase I and pharmacokinetic study of XR5944.14, a novel agent with a unique mechanism of action
a
b
c
d
e
f
a
|
|
Author keywords
Phase I; Solid tumours; XR5944.14
|
|
Indexed keywords
ANTIBIOTIC AGENT;
ANTIBODY;
CYTOTOXIC AGENT;
GEMCITABINE;
MITOMYCIN C;
NITROSOUREA;
PIPERACILLIN PLUS TAZOBACTAM;
STEROID;
UNCLASSIFIED DRUG;
XR 594414;
ACUTE KIDNEY FAILURE;
AGED;
ALOPECIA;
ANTINEOPLASTIC ACTIVITY;
AREA UNDER THE CURVE;
ARTHRALGIA;
ARTICLE;
BLOOD TOXICITY;
CLINICAL ARTICLE;
CLINICAL TRIAL;
COLITIS;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DIARRHEA;
DNA TRANSCRIPTION;
DRUG DISTRIBUTION;
DRUG DOSE ESCALATION;
DRUG DOSE INCREASE;
DRUG EFFICACY;
DRUG INHIBITION;
DRUG MECHANISM;
DRUG STRUCTURE;
DRUG WITHDRAWAL;
ELECTROCARDIOGRAM;
FATIGUE;
FEBRILE NEUTROPENIA;
FEMALE;
FEVER;
HUMAN;
INJECTION SITE REACTION;
KIDNEY CLEARANCE;
LIQUID CHROMATOGRAPHY;
MALE;
MAXIMUM TOLERATED DOSE;
MUCOSA INFLAMMATION;
MULTICENTER STUDY;
MULTIPLE CYCLE TREATMENT;
MYALGIA;
NAUSEA;
NEUTROPENIA;
ORAL MUCOSAL DISEASE;
PERIPHERAL EDEMA;
PHASE 1 CLINICAL TRIAL;
PRIORITY JOURNAL;
QT PROLONGATION;
SEPSIS;
SOLID TUMOR;
TANDEM MASS SPECTROMETRY;
TREATMENT RESPONSE;
VOMITING;
ADULT;
AGED;
AREA UNDER CURVE;
FEMALE;
HUMANS;
INFUSIONS, INTRAVENOUS;
MALE;
MAXIMUM TOLERATED DOSE;
MIDDLE AGED;
NEOPLASMS;
PHENAZINES;
|
|
EID: 34948887185
PISSN: 00070920
EISSN: 15321827
Source Type: Journal
DOI: 10.1038/sj.bjc.6603953 Document Type: Article |
|
Times cited : (16)
|
|
References (9)
|
